表观扩散系数早期变化可预测中高危前列腺癌对新辅助雄激素剥夺联合外照射放疗的反应
这项前瞻性研究纳入12例中高危前列腺癌患者,在nADT和EBRT期间多个时间点行mpMRI和PSA检测,发现tADC从基线到nADT开始后8周显著升高,且该早期变化与治疗后PSA相关,良好反应者tADC升高幅度更大。
要点
- 中高危前列腺癌nADT开始后8周,肿瘤ADC较基线显著升高。
- 基线至8周的tADC变化与治疗后PSA相关(r=-0.666,p=0.02)。
- 治疗后PSA<0.1 ng/ml者早期tADC升高幅度更大(p=0.03)。
核心结论
- 这项先导研究提示,早期ADC指标可能作为中高危前列腺癌对nADT和EBRT反应的生物标志物。
研究设计与样本
- HIPAA合规、IRB批准的前瞻性研究,纳入12例中高危前列腺癌患者,在基线、nADT开始后8周、EBRT第6周和nADT开始后6个月行血清PSA和多参数前列腺MRI检查。
关键影像表现/征象
- 肿瘤ADC从基线至nADT开始后8周显著升高(917.8 ± 107.7 × 10-6 vs 1033.8 ± 139.3 × 10-6 mm2/s,p<0.01),TP2和TP3无进一步变化。
- 治疗后PSA在良好反应者(<0.1 ng/ml)与不良反应者(≥0.1 ng/ml)间,基线至TP1的tADC变化幅度分别为169.2 ± 122.4 × 10-6 mm2/s与22.9 ± 75.5 × 10-6 mm2/s(p=0.03)。
诊断标准与关键数值
- 良好反应定义为治疗后PSA<0.1 ng/ml,不良反应定义为治疗后PSA≥0.1 ng/ml。
- 基线至TP1的tADC百分比变化与治疗后PSA相关(r=-0.666,p=0.02),绝对变化亦相关(r=-0.674,p=0.02)。
临床应用与阅片要点
- 中高危前列腺癌患者nADT开始后8周行mpMRI测量tADC变化,可能有助于早期评估治疗反应。
- 报告时应关注肿瘤ADC从基线至nADT后8周的百分比和绝对值变化,而非后续时间点的进一步变化。
局限性
- 原文称本研究为先导研究(pilot study)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To determine the role of serial apparent diffusion coefficient (ADC) as a biomarker for response to neoadjuvant androgen deprivation therapy (nADT) followed by external beam radiation therapy (EBRT) in intermediate- to high-risk prostate cancer (PCa) patients.
METHODS: This Health Insurance Portability and Accountability Act (HIPAA)-compliant, institutional review board (IRB)-approved prospective study included 12 patients with intermediate- to high-risk PCa patients prior to nADT and EBRT, who underwent serial serum prostate-specific antigen (PSA) and multiparametric prostate magnetic resonance imaging (mpMRI) at baseline (BL), 8-weeks after nADT initiation (time point [TP]1), 6-weeks into EBRT delivery (TP2), and 6-months after nADT initiation (TP3). Tumour volume (tVOL) and tumour and normal tissue ADC (tADC and nlADC) were determined at all TPs. tADC and nlADC dynamics were correlated with post-treatment PSA using Pearson's correlation coefficient. Paired t-tests compared pre/post-treatment ADC.
RESULTS: There was a sequential decrease in PSA at all TPs, reaching their lowest values at TP3 post-treatment completion. Mean tADC increased significantly from baseline to TP1 (917.8 ± 107.7 × 10-6 versus 1033.8 ± 139.3 × 10-6 mm2/s; p<0.01), with no subsequent change at TP2 or TP3. Both percentage and absolute change in tADC from BL to TP1 correlated with post-treatment PSA (r=-0.666, r=-0.674; p=0.02). Post-treatment PSA in good responders (<0.1 ng/ml) versus poor responders (≥ 0.1 ng/ml) was associated with a greater increase in tADC from BL to TP1 (169.2 ± 122.4 × 10-6 versus 22.9 ± 75.5 × 10-6 mm2/s, p=0.03).
CONCLUSION: This pilot study demonstrates the potential for early ADC metrics as a biomarker of response to nADT and EBRT in intermediate to high-risk PCA.
引用
- Franco FB, Leeman JE, Fedorov A, et al. Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer. Clin Radiol. 2024. PMID: 38302377. doi:10.1016/j.crad.2023.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。